Myeloma Forecast for 2016: What’s exciting, what’s real…and who do you trust?

As we start off 2016, there is excitement in the air. Three new drug approvals, the Black Swan Research Initiative® is moving strongly into cure trials; it seems that we have myeloma on the run! Yet the reality is that we all know friends, support group members, patients who are not doing well, whose lives are threatened by myeloma despite all that is new and wonderful.

MRD testing in myeloma takes center stage

Last week’s 4th Annual ESLHO (European Scientific foundation of Laboratory Hemato Oncology) Symposium in Zurich, Switzerland was the first ever dedicated exclusively to examining “New Developments in MRD Diagnostics.” The two-day event provided a comprehensive review of the current status of MRD (minimal residual disease) testing and future optio

Bruno Paiva Wins Prestigious Young Investigator Award at the International Myeloma Workshop in Rome

During the “Rising Stars” session on Saturday, Sept. 26th at the International Myeloma Workshop (IMW) in Rome—co-chaired by IMW organizer Dr. Antonio Palumbo and myself—Dr. Bruno Paiva from the University of Navarra in Pamplona, Spain was awarded the newly established Bart Barlogie Young Investigator Award.

Black Swan Research Initiative® Update

The Black Swan Research Initiative® (BSRI) is on the brink of several key steps forward, I am happy to report.  Great progress has already been made.

Black Swan Research Initiative: As We Move Ahead, What Will We Learn?

The Black Swan Research Initiative team has been busy since our spring launch. Team members are laying the groundwork for clinical trials and perfecting the extra-sensitive testing regimes that will allow us to measure minimal residual disease, identify pathways to cures, and improve treatments along the way. 

Pages